SENP1: A Potential Drug Target and Biomarker for SUMO-Specific Peptidase 1

Target Name: SENP1

NCBI ID: G29843

SENP1: A Potential Drug Target and Biomarker for SUMO-Specific Peptidase 1

SUMO-specific peptidase 1 (SENP1) is a protein that plays a crucial role in the ubiquitin-proteasome system (UPS), which is responsible for the degradation of damaged or unnecessary proteins in the cell. Mutations in SENP1 have been linked to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. As a result, targeting SENP1 has become an attractive research focus with the potential to develop new treatments for a variety of diseases.

SENP1 functions as an essential enzyme in the UPS, breaking down a protein called ubiquitin. Ubiquitin is a large protein that functions as a tag for proteins, allowing them to be targeted for degradation by the UPS. SENP1 is specifically involved in the degradation of Ubiquitin-conjugated proteins, which are involved in a wide range of cellular processes, including cell signaling, DNA replication, and stress response.

SENP1 has been shown to play a key role in the regulation of cellular processes that are important for human health and disease. For example, studies have shown that SENP1 is involved in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. In addition, SENP1 has been linked to the development of cancer, including colon cancer.

SENP1 also has potential as a biomarker for a variety of diseases. For example, SENP1 has been shown to be overexpressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. In addition, SENP1 has been shown to be involved in the regulation of cellular signaling pathways, which can be important targets for drugs that target signaling pathways associated with disease.

Targeting SENP1 has the potential to be a highly effective way to treat a variety of diseases. For example, SENP1 has been shown to be involved in the development of neurodegenerative disorders, and drugs that target SENP1 have been shown to be effective in treating these disorders. In addition, SENP1 has been shown to be involved in the regulation of cellular signaling pathways, which can be important targets for drugs that target signaling pathways associated with disease.

In conclusion, SENP1 is a protein that plays a crucial role in the ubiquitin-proteasome system and has been shown to be involved in the development and progression of a variety of diseases. As a result, targeting SENP1 has the potential to be a highly effective way to treat a variety of diseases. Further research is needed to fully understand the role of SENP1 in disease and to develop effective treatments.

Protein Name: SUMO Specific Peptidase 1

Functions: Protease that catalyzes two essential functions in the SUMO pathway (PubMed:10652325, PubMed:15199155, PubMed:16253240, PubMed:16553580, PubMed:21829689, PubMed:21965678, PubMed:23160374, PubMed:24943844, PubMed:25406032, PubMed:29506078). The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins. The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. Deconjugates SUMO1 from HIPK2 (PubMed:16253240). Deconjugates SUMO1 from HDAC1 and BHLHE40/DEC1, which decreases its transcriptional repression activity (PubMed:21829689). Deconjugates SUMO1 from CLOCK, which decreases its transcriptional activation activity (PubMed:23160374). Deconjugates SUMO2 from MTA1 (PubMed:21965678). Deconjugates SUMO1 from METTL3 (PubMed:29506078). Desumoylates CCAR2 which decreases its interaction with SIRT1 (PubMed:25406032). Deconjugates SUMO1 from GPS2 (PubMed:24943844)

More Common Targets